［Abstract］　Postural instability and gait disorder dominant(PIGD) is one of the main symptoms in patients with Parkinson′s disease(PD). However, PIGD is often neglected in the early stage of the disease and fails to be recognized and diagnosed in time. With the progression of the disease, gait abnormalities and disorders are more prominent, and freezing of gait(FOG) occurs in severe cases, which increases the risk of falls, fractures and even death and seriously afflicts the life and work of PD patients. On the one hand, identifying gait disorders early is a key point in the diagnosis of PD and has important clinical significance for achieving early treatment of PD. On the other hand, although there are many clinical treatments for PIGD in PD at present, their clinical effects are not clear, and there is still a lack of effective therapeutic intervention means and methods. This paper reviews the progress in the evaluation, diagnosis and current status of treatment of PIGD in PD patients, providing a valuable reference for the diagnosis and treatment of PD patients.]]> 2022/12/30 11:06:43 TANG Hong-yin, LIAO Xiang-lian, ZHANG Rui, et al. 5true ［Abstract］　Objective　To explore the correlation between plasma DYRK1A, tau, p-tau levels and cognitive dysfunction in patients with Parkinson′s disease(PD) and their diagnostic value of cognitive dysfunction in PD. Methods　Eighty-seven patients with PD were included as the research subjects, and their general data were collected. The patients were divided into normal cognitive function group(PD-NC group, 17 cases), mild cognitive impairment group(PD-MCI group, 30 cases) and dementia group(PDD group, 40 cases) according to their different Montreal Cognitive Assessment(MoCA) Scale scores. Enzyme-linked immunosorbent assay was used to detect the levels of DYRK1A, tau and p-tau in the plasma of the subjects. The differences in the levels of DYRK1A, tau and p-tau were compared among different cognitive function groups, and the diagnostic efficacy of these three indicators for PD dementia was analyzed. Results　The level of plasma DYRK1A in the PD-NC group was significantly lower than that in the PD-MCI group(P=0.033) and the PDD group(P=0.005), but there was no significant difference between the PD-MCI group and the PDD group(P=0.468). The tau level in the PD-NC group was significantly lower than that in the PDD group(P=0.006), but there was no significant difference between the PD-NC group and the PD-MCI group as well as between the PD-MCI group and the PDD group(P>0.05). There was no significant difference in p-tau level among the three groups(P>0.05). The results of receiver operating characteristic(ROC) curve showed that tau protein had application value in diagnosis of PD dementia［the area under the curve(AUC)=0.658, P=0.012］, and its optimum cut-off value was 175.88 pg/ml, with a corresponding sensitivity being 75.00% and a specificity being 55.30%. The tau protein combined with DYRK1A or p-tau, or the combination of the three indicators could improve the diagnostic efficacy, among which the combination of the three indicators of DYRK1A+tau+p-tau had the highest diagnostic efficacy(AUC=0.688). The single indicator DYRK1A or p-tau had no significant application value in diagnosis of PD dementia(P>0.05). Conclusion　There are significant differences in plasma DYRK1A and tau levels in PD patients with different cognitive dysfunction. Tau levels have diagnostic efficacy for PD dementia, and combined detections can improve the sensitivity of the diagnosis to some extent.]]> 2022/12/30 0:00:00 CAI Qian, ZHANG Yang, LIU Na, et al. 4true ［Abstract］　Parkinson′s disease(PD) is a common neurodegenerative disorder. Chaihujialonggumuli decoction is originated from Treatise on Febrile Diseases, in which the main symptoms are described in consistent with a variety of motor and non-motor symptoms of PD. Chaihujialonggumuli decoction often has better curative effects on treating diseases with the core clinical manifestations of “ full chest, annoyance and terror”. Modern studies also suggest that Chaihujialonggumuli decoction has certain effects on PD-related symptoms. An overview of theory and practice in the treatment of Parkinson′s disease with Chaihujialonggumuli decoction is presented in this paper.]]> 2022/12/30 11:06:44 SHEN Qi, LI Zhe, SU Qiao-zhen, et al. 3true ［Abstract］　Objective　To analyse the clinical features of Parkinson′s disease(PD) patients in southern China based on gender and age of onset. Methods　A total of 1 300 PD patients［including 739 males and 561 females, and 200 early-onset PD(EOPD) patients and 1 100 late-onset PD(LOPD) patients］ were selected from Guangdong Second Provincial General Hospital during 2017 and 2019, all of whom completed the assessment of all the scales. Results　(1)The female PD patients had a younger mean age of onset, more severe anxiety, more depression, and more headache, and a higher incidence of tremor as the first symptom compared with the male PD patients and the differences were significant(P<0.05). (2)The LOPD patients had an older mean age of onset, shorter disease duration, faster disease progression, significantly higher rates of constipation, significantly higher rates of libido changes, and a lower incidence of stiffness as the first symptom compared with the EOPD patients and the differences were significant(P<0.05). Conclusion　In southern China, there are differences in the clinical symptoms of PD patients according to age of onset and gender.]]> 2022/12/30 0:00:00 TANG Hong-yin, LIAO Xiang-lian, LI Gui-hua 2true ［Abstract］　Parkinson′s disease(PD) is the second common neurodegenerative disease, for which there is no effective treatment currently. The treatment of PD mainly relies on drugs to delay the progression of the disease. PD is the result of genetics, environment and aging, and its pathogenesis is complex. Neuroinflammation is an important link to the pathogenesis of PD. Recent studies have reported that neuroinflammation induced by the activation of nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3) inflammasome plays an important role in the pathogenic mechanism of PD, revealing that the inflammasome may be a potential therapeutic target for PD. Therefore, this paper discusses the activation mechanism as well as the possible pathogenic mechanism of NLRP3 inflammasome in PD, and probes new therapies of PD by targeting the NLRP3 inflammasome, so as to provide reference evidence for further understanding the exact role of NLRP3 inflammasome in PD and exploring new therapeutic strategies for PD treatment.]]> 2022/12/30 11:06:44 JIAO Xue, HUANG Shu-xuan 1true